The concept of treatment-free remission in chronic myeloid leukemia von Saußele, S, Richter, J, Hochhaus, A, Mahon, F-X

Volltext

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial von Hochhaus, A, Saglio, G, Hughes, T P, Larson, R A, Kim, D-W, Issaragrisil, S, le Coutre, P D, Etienne, G, Dorlhiac-Llacer, P E, Clark, R E, Flinn, I W, Nakamae, H, Donohue, B, Deng, W, Dalal, D, Menssen, H D, Kantarjian, H M

Volltext

Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation von Heidel, F., Hochhaus, A.

Volltext

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias von Cortes, J.E, Kim, D.-W, Pinilla-Ibarz, J, le Coutre, P, Paquette, R, Chuah, C, Nicolini, F.E, Apperley, J.F, Khoury, H.J, Talpaz, M, DiPersio, J, DeAngelo, D.J, Abruzzese, E, Rea, D, Baccarani, M, Müller, M.C, Gambacorti-Passerini, C, Wong, S, Lustgarten, S, Rivera, V.M, Clackson, T, Turner, C.D, Haluska, F.G, Guilhot, F, Deininger, M.W, Hochhaus, A, Hughes, T, Goldman, J.M, Shah, N.P, Kantarjian, H

Volltext

Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up von Hochhaus, A., Saussele, S., Rosti, G., Mahon, F.-X., Janssen, J.J.W.M., Hjorth-Hansen, H., Richter, J., Buske, C.

Volltext

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation von La Rosée, F., Bremer, H. C., Gehrke, I., Kehr, A., Hochhaus, A., Birndt, S., Fellhauer, M., Henkes, M., Kumle, B., Russo, S. G., La Rosée, P.

Volltext

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia von Cross, N C P, White, H E, Colomer, D, Ehrencrona, H, Foroni, L, Gottardi, E, Lange, T, Lion, T, Machova Polakova, K, Dulucq, S, Martinelli, G, Oppliger Leibundgut, E, Pallisgaard, N, Barbany, G, Sacha, T, Talmaci, R, Izzo, B, Saglio, G, Pane, F, Müller, M C, Hochhaus, A

Volltext

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia von Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., Hjorth-Hansen, H., Hughes, T. P., Janssen, J. J. W. M., Kantarjian, H. M., Kim, D. W., Larson, R. A., Lipton, J. H., Mahon, F. X., Mayer, J., Nicolini, F., Niederwieser, D., Pane, F., Radich, J. P., Rea, D., Richter, J., Rosti, G., Rousselot, P., Saglio, G., Saußele, S., Soverini, S., Steegmann, J. L., Turkina, A., Zaritskey, A., Hehlmann, R.

Volltext

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV von Kalmanti, L, Saussele, S, Lauseker, M, Müller, M C, Dietz, C T, Heinrich, L, Hanfstein, B, Proetel, U, Fabarius, A, Krause, S W, Rinaldetti, S, Dengler, J, Falge, C, Oppliger-Leibundgut, E, Burchert, A, Neubauer, A, Kanz, L, Stegelmann, F, Pfreundschuh, M, Spiekermann, K, Scheid, C, Pfirrmann, M, Hochhaus, A, Hasford, J, Hehlmann, R

Volltext

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia von Steegmann, J L, Baccarani, M, Breccia, M, Casado, L F, García-Gutiérrez, V, Hochhaus, A, Kim, D-W, Kim, T D, Khoury, H J, Le Coutre, P, Mayer, J, Milojkovic, D, Porkka, K, Rea, D, Rosti, G, Saussele, S, Hehlmann, R, Clark, R E

Volltext

Profiling neurotransmitters in a crustacean neural circuit for locomotion von Schneider, Anna C, Seichter, Henriette A, Neupert, Susanne, Hochhaus, A Maren, Smarandache-Wellmann, Carmen R

Volltext

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) von Hanfstein, B, Müller, M C, Hehlmann, R, Erben, P, Lauseker, M, Fabarius, A, Schnittger, S, Haferlach, C, Göhring, G, Proetel, U, Kolb, H-J, Krause, S W, Hofmann, W-K, Schubert, J, Einsele, H, Dengler, J, Hänel, M, Falge, C, Kanz, L, Neubauer, A, Kneba, M, Stegelmann, F, Pfreundschuh, M, Waller, C F, Branford, S, Hughes, T P, Spiekermann, K, Baerlocher, G M, Pfirrmann, M, Hasford, J, Saußele, S, Hochhaus, A

Volltext

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia von Hochhaus, A, O'Brien, S G, Guilhot, F, Druker, B J, Branford, S, Foroni, L, Goldman, J M, Müller, M C, Radich, J P, Rudoltz, M, Mone, M, Gathmann, I, Hughes, T P, Larson, R A

Volltext

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study von Hochhaus, A, Masszi, T, Giles, F J, Radich, J P, Ross, D M, Gómez Casares, M T, Hellmann, A, Stentoft, J, Conneally, E, García-Gutiérrez, V, Gattermann, N, Wiktor-Jedrzejczak, W, le Coutre, P D, Martino, B, Saussele, S, Menssen, H D, Deng, W, Krunic, N, Bedoucha, V, Saglio, G

Volltext

Standardized definitions of molecular response in chronic myeloid leukemia von Cross, N C P, White, H E, Müller, M C, Saglio, G, Hochhaus, A

Volltext

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry von Hoffmann, V S, Baccarani, M, Hasford, J, Castagnetti, F, Di Raimondo, F, Casado, L F, Turkina, A, Zackova, D, Ossenkoppele, G, Zaritskey, A, Höglund, M, Simonsson, B, Indrak, K, Sninska, Z, Sacha, T, Clark, R, Bogdanovic, A, Hellmann, A, Griskevicius, L, Schubert-Fritschle, G, Sertic, D, Guilhot, J, Lejniece, S, Zupan, I, Burgstaller, S, Koskenvesa, P, Everaus, H, Costeas, P, Lindoerfer, D, Rosti, G, Saussele, S, Hochhaus, A, Hehlmann, R

Volltext

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants von Hehlmann, R, Lauseker, M, Saußele, S, Pfirrmann, M, Krause, S, Kolb, H J, Neubauer, A, Hossfeld, D K, Nerl, C, Gratwohl, A, Baerlocher, G M, Heim, D, Brümmendorf, T H, Fabarius, A, Haferlach, C, Schlegelberger, B, Müller, M C, Jeromin, S, Proetel, U, Kohlbrenner, K, Voskanyan, A, Rinaldetti, S, Seifarth, W, Spieß, B, Balleisen, L, Goebeler, M C, Hänel, M, Ho, A, Dengler, J, Falge, C, Kanz, L, Kremers, S, Burchert, A, Kneba, M, Stegelmann, F, Köhne, C A, Lindemann, H W, Waller, C F, Pfreundschuh, M, Spiekermann, K, Berdel, W E, Müller, L, Edinger, M, Mayer, J, Beelen, D W, Bentz, M, Link, H, Hertenstein, B, Fuchs, R, Wernli, M, Schlegel, F, Schlag, R, de Wit, M, Trümper, L, Hebart, H, Hahn, M, Thomalla, J, Scheid, C, Schafhausen, P, Verbeek, W, Eckart, M J, Gassmann, W, Pezzutto, A, Schenk, M, Brossart, P, Geer, T, Bildat, S, Schäfer, E, Hochhaus, A, Hasford, J

Volltext

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance von HOCHHAUS, A, LA ROSEE, P

Volltext

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML von Schütz, C, Inselmann, S, Sausslele, S, Dietz, C T, Müller, M C, Eigendorff, E, Brendel, C A, Metzelder, S K, Brümmendorf, T H, Waller, C, Dengler, J, Goebeler, M E, Herbst, R, Freunek, G, Hanzel, S, Illmer, T, Wang, Y, Lange, T, Finkernagel, F, Hehlmann, R, Huber, M, Neubauer, A, Hochhaus, A, Guilhot, J, Xavier Mahon, F, Pfirrmann, M, Burchert, A

Volltext

Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia von Jabbour, E, Deininger, M, Hochhaus, A

Volltext